Although several prognostic biomarkers for GC have been undergoing or tested in clinical trials such as Fibroblast Growth Factor Receptor (FGFR) [21], Human Epidermal Growth Factor Receptor 2 (HER2) [22], Epidermal Growth Factor Receptor (EGFR) [23], Hepatocyte Growth Factor Receptor (HGFR) [24], etc, many more potential and valuable molecular biomarkers are urgent to be discovered and identified to improve the clinical outcome of patients with GC. The gene discussed is MET; the disease is gastric cancer.